bexarotene has been researched along with vorozole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bode, AM; Christov, K; Ericson, ME; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE; Szabo, E | 1 |
| Garbow, JR; He, J; Higashikubo, R; Jones, LA; Lubet, RA; Mach, RH; Rowland, D; Shoghi, KI; Su, Y; Tu, Z; Wheeler, KT; Xu, J; Yan, Y; You, M | 1 |
2 other study(ies) available for bexarotene and vorozole
| Article | Year |
|---|---|
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; Carcinogens; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Triazoles | 2008 |
Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Apoptosis; Benzamides; Bexarotene; Blotting, Western; Cell Proliferation; Female; Flow Cytometry; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Ligands; Mammary Neoplasms, Animal; Methylnitrosourea; Mice; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Receptors, sigma; Tetrahydronaphthalenes; Triazoles; Tumor Cells, Cultured | 2013 |